Clinical Remission in Asthma: An Expert Consensus on the Current Criteria, Evidence, and Impact
This activity is provided by National Jewish Health and supported by an independent educational grant from AstraZeneca Pharmaceuticals.
Credits Available: 1.0 AMA PRA Category 1 Credit™
Activity Release Date: September 29, 2025
Activity Expiration Date: September 29, 2026
Activity Description
This is a journal-based CME activity based on the article supplement, Clinical Remission in Asthma: An Expert Consensus on the Current Criteria, Evidence, and Impact (J Allergy Clin Immunol 2025;156:S1-24).
Striving for clinical remission in asthma is a new approach to treatment whose time has come. It is critical that a widely accepted definition of asthma clinical remission be developed that is agreed to be both practical and meaningful to clinicians, researchers, and patients. To advance this development process, National Jewish Health convened a panel of experts in the field for a 2-day virtual workshop to critically assess previously proposed definitions of remission in asthma and other immune-mediated diseases and the latest evidence from clinical studies of remission in patients with asthma treated with biologic therapies. This supplement presents the panel’s definition of asthma clinical remission and identifies unresolved issues that deserve further investigation and wider discussion among different stakeholder groups.
Learning Objectives
1. Define clinical remission as a treatment goal in asthma.
2. Cite evidence that biologic therapies can induce clinical remission in patients with severe asthma.
3. Identify the implications of targeting asthma remission for patients, clinicians, and researchers.
Accreditation
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
National Jewish Health designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Participation
- Review the accreditation and disclosure information
- Read the supplement, Clinical Remission in Asthma: An Expert Consensus on the Current Criteria, Evidence, and Impact: https://www.sciencedirect.com/journal/journal-of-allergy-and-clinical-immunology/vol/156/issue/3/suppl/S
- Complete the post-test and evaluation: https://redcap.link/Asthma-Remission-Supplement-CME (Opens in a new window).
- Your CME certificate will be available for download once you submit the post-test and evaluation.
Conflicts of Interest Disclosure Policy
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties.
All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Planner and Reviewer Disclosures
Meghan Brenner, MA has no relevant financial relationships to report.
Andrea Harshman, MHA, CHCP, CMP-HC has no relevant financial relationships to report.
Rohit K. Katial, MD reports the following relevant financial relationships:
Advisory Board: AstraZeneca, GlaxoSmithKline, Grifols, and Sanofi/Regeneron
Speaker: AstraZeneca, Grifols, Pharming, and Sanofi/Regeneron
Esther Langmack, MD, CHCP has no relevant financial relationships to report.
Harold Nelson, MD has no relevant financial relationships to report.
Michael E. Wechsler, MD, MMSc reports the following relevant financial relationships:
Consultant: Amgen, Areteia Therapeutics, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Celldex, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GlaxoSmithKline, Incyte, Kinaset, Merck, Novartis, OM Pharma, Overtone Therapeutics/Foresite Labs, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi/Genzyme, Sentien Biotechnologies, Sound Biologics, Tetherex, Pharmaceuticals, Teva, and Upstream Bio.
Disclaimer Statement
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME). We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities. https://www.nationaljewish.org/education/pro-ed/policies
Questions
For questions about the accreditation of this activity, contact ProEd@njhealth.org.
Clinical Remission in Asthma: An Expert Consensus on the Current Criteria, Evidence, and Impact